PBB2 Antibody

What is the PB2 subunit and why is it important in influenza research?

The PB2 subunit is one of three proteins (along with PB1 and PA) that form the RNA-dependent RNA polymerase complex essential for influenza virus replication. This complex is responsible for both transcription of viral mRNAs and replication of the viral genome. The PB2 subunit specifically recognizes and binds host cell mRNA caps, facilitating the "cap-snatching" mechanism that is critical for viral mRNA synthesis. Research targeting PB2 is valuable because this subunit plays a fundamental role in viral replication processes and has been associated with host range determination and virulence of influenza viruses. Anti-PB2 antibodies allow scientists to track, quantify, and study this protein's expression and function without interfering with the virus's replication cycle .

How does the Anti-PB2 clone# 3-1.6 differ from neutralizing antibodies?

Anti-PB2 clone# 3-1.6 is distinguished by its ability to bind specifically to the PB2 subunit through antigen-antibody reactions without neutralizing viral activity. Unlike neutralizing antibodies that prevent viral infection by blocking receptor binding, fusion, or other critical viral functions, Anti-PB2 (3-1.6) allows the virus to maintain its normal replication cycle while enabling researchers to detect and study the polymerase complex. This non-neutralizing property makes it particularly valuable for experiments where viral replication needs to be monitored without interference, such as in drug screening assays for anti-influenza agents and studies examining polymerase activity in various influenza strains .

What influenza virus strains can be studied using the Anti-PB2 (clone# 3-1.6) antibody?

The Anti-PB2 (clone# 3-1.6) antibody demonstrates broad reactivity across type A influenza viruses from both human and avian sources. According to experimental data, this antibody successfully binds to PB2 from multiple influenza subtypes including H1N1, H3N2, H5N1, H7N9, and H9N2 as demonstrated in ultracentrifugation analysis studies. This broad spectrum of reactivity makes it an exceptionally versatile tool for comparative studies across different influenza strains, particularly when examining polymerase function in seasonal, pandemic, and potential pandemic strains .

How can Anti-PB2 antibody be used to study polymerase complex formation during different stages of viral replication?

To study polymerase complex formation during viral replication using Anti-PB2 antibody, researchers can implement time-course experiments combining immunoprecipitation with Western blotting. The experimental approach involves:

• Infecting cells with influenza virus and collecting samples at different time points post-infection (e.g., 2, 4, 8, 12, 24 hours)

• Performing immunoprecipitation using Anti-PB2 (clone# 3-1.6) at a 1:1,000 dilution

• Analyzing precipitated complexes by Western blotting for PB2 and co-precipitated PB1, PA, and other interacting proteins

• Quantifying the relative amounts of each component at different time points

This methodology allows researchers to track the assembly kinetics of the polymerase complex throughout the viral life cycle. The non-neutralizing property of Anti-PB2 (3-1.6) ensures that the natural progression of viral replication remains unaffected, providing authentic data on complex formation dynamics. Additionally, researchers can combine this approach with subcellular fractionation to determine the localization of polymerase complexes within the cell at different replication stages .

What structural insights can be gained by combining Anti-PB2 antibody studies with computational epitope profiling?

Combining Anti-PB2 antibody experimental data with computational epitope profiling can provide significant structural insights into the PB2 protein and its interactions. This integrated approach involves:

• Using Anti-PB2 (clone# 3-1.6) for experimental epitope mapping, determining the binding region (known to be within amino acids 530-759 of H1N1 PB2)

• Applying structural modeling tools like SPACE2 to predict the three-dimensional configurations of antibody-antigen complexes

• Identifying critical binding residues and potential conformational changes upon binding

• Using this information to infer functional domains within the PB2 protein

The structural insights gained from this approach can reveal how PB2 interacts with host factors, identify conserved epitopes across influenza strains, and potentially guide structure-based drug design targeting the polymerase complex. Recent advances in computational methods like SPACE2 allow for more accurate clustering of antibodies by epitope, which can help identify functionally important regions of the PB2 protein that might serve as targets for antiviral development .

How can the PB2 antibody be employed in assessing host adaptation markers in avian influenza strains?

To assess host adaptation markers in avian influenza strains using PB2 antibody, researchers can implement a comparative analysis methodology:

• Collect avian influenza virus isolates and laboratory-adapted strains that show different host tropism

• Extract viral proteins or perform direct immunoprecipitation from infected cells using Anti-PB2 (clone# 3-1.6)

• Analyze PB2 protein using Western blotting and mass spectrometry to identify post-translational modifications

• Map specific amino acid changes that correlate with mammalian adaptation (particularly positions 627 and 701, known adaptation markers)

• Perform functional polymerase assays in both avian and mammalian cell lines, using the antibody to track PB2 localization and interactions

This approach leverages the ability of Anti-PB2 (clone# 3-1.6) to recognize PB2 from multiple avian influenza subtypes (H5N1, H7N9, H9N2) as well as human-adapted strains (H1N1, H3N2). The data from such studies can help identify molecular signatures associated with cross-species transmission potential, which is crucial for pandemic risk assessment and surveillance efforts .

What are the optimal conditions for Western blotting using Anti-PB2 (clone# 3-1.6)?

For optimal Western blotting results with Anti-PB2 (clone# 3-1.6), researchers should follow this methodological protocol:

• Sample preparation:

  • Load approximately 10 μg of protein per lane

  • Include appropriate positive controls (e.g., lysates from cells expressing recombinant PB2)

• Antibody dilutions:

  • Primary antibody (Anti-PB2 clone# 3-1.6): 1:1,000 dilution (1 μg/mL)

  • Secondary antibody (Anti-Mouse IgG-HRP): 1:2,000 dilution

• Incubation conditions:

  • Primary antibody: Overnight at 4°C or 2 hours at room temperature

  • Secondary antibody: 1 hour at room temperature

• Washing and detection:

  • Use PBS with 0.1% Tween-20 for washing (4-5 washes, 5 minutes each)

  • Employ enhanced chemiluminescence (ECL) detection systems for visualization

This protocol has been experimentally validated to detect PB2 from multiple influenza A virus subtypes including H1N1 and H3N2. For avian influenza viruses (H5N1, H7N9, H9N2), the same protocol applies, though researchers might need to verify band sizes as slight variations in molecular weight can occur between strains .

How can immunoprecipitation with Anti-PB2 be optimized for studying polymerase complex interactions?

To optimize immunoprecipitation with Anti-PB2 for studying polymerase complex interactions, follow this detailed methodology:

• Sample preparation:

  • Harvest cells 24-48 hours post-infection or transfection

  • Lyse cells in a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% NP-40, and protease inhibitors

  • Clear lysates by centrifugation (14,000 × g, 10 minutes, 4°C)

• Immunoprecipitation procedure:

  • Pre-clear lysate with protein G beads (1 hour, 4°C)

  • Add Anti-PB2 (clone# 3-1.6) at 1-2 μg per 500 μg of total protein

  • Incubate overnight at 4°C with gentle rotation

  • Add protein G beads and incubate for 2-3 hours at 4°C

  • Wash beads 4 times with lysis buffer and once with PBS

• Co-immunoprecipitation considerations:

  • For detecting weakly associated partners, use gentler detergents (0.1% NP-40)

  • Consider crosslinking approaches for transient interactions

  • Include RNase treatment controls to distinguish RNA-mediated from direct protein-protein interactions

• Analysis of precipitated complexes:

  • Elute proteins by boiling in SDS-PAGE loading buffer

  • Analyze by Western blotting for PB2 and suspected interacting partners (PB1, PA, NP)

  • Consider mass spectrometry for unbiased identification of novel interaction partners

This optimized protocol enables the identification of both stable and transient interaction partners of the PB2 protein, providing insights into the dynamic assembly of the viral polymerase complex and its interactions with host factors .

What approaches can be used to combine Anti-PB2 antibody detection with structural analysis techniques?

Researchers can integrate Anti-PB2 antibody detection with structural analysis using the following methodological approaches:

When implementing ultracentrifugation analysis, researchers should note that PB2 from various influenza subtypes (H1N1, H3N2, H5N1, H7N9, H9N2) shows similar sedimentation profiles when complexed with Anti-PB2 (clone# 3-1.6). These approaches can be particularly valuable for understanding how the antibody recognizes its epitope within amino acids 530-759 of the PB2 protein, potentially revealing structural features that are conserved across influenza subtypes .

Why might Western blotting with Anti-PB2 antibody show unexpected band patterns, and how should these be interpreted?

When Western blotting with Anti-PB2 antibody shows unexpected band patterns, researchers should systematically evaluate several possible explanations:

• Multiple bands at different molecular weights:

  • Expected PB2 molecular weight is approximately 85-90 kDa

  • Lower molecular weight bands may indicate proteolytic degradation (solution: add additional protease inhibitors)

  • Higher molecular weight bands may indicate post-translational modifications like ubiquitination or SUMOylation

  • Very high molecular weight bands (>150 kDa) could represent undissociated complexes (solution: increase SDS concentration or boiling time)

• Strain-specific variations:

  • Different influenza strains may show slight variations in PB2 molecular weight

  • Compare observed bands with predicted molecular weights from sequence data

  • Consider running controls with recombinant PB2 from specific strains

• Cross-reactivity considerations:

  • While Anti-PB2 (clone# 3-1.6) is highly specific, extremely high antibody concentrations may increase background

  • Optimal dilution is 1:1,000 (1 μg/mL) for Western blotting applications

• Signal intensity variations:

  • PB2 expression levels vary during the viral life cycle

  • Nuclear/cytoplasmic fractionation may be needed to detect PB2 in early infection stages

  • Consider using more sensitive detection methods for low abundance samples

To validate band identity, researchers can perform peptide competition assays using the immunogen (recombinant PB2 amino acids 530-759) or conduct knockdown experiments in systems using recombinant PB2 expression .

How can researchers distinguish between specific and non-specific binding when using Anti-PB2 in complex experimental systems?

To distinguish between specific and non-specific binding when using Anti-PB2 antibody in complex experimental systems, implement these methodological controls and analytical approaches:

• Essential experimental controls:

  • Negative control: Uninfected/untransfected cells processed identically

  • Isotype control: Irrelevant mouse IgG1 antibody at the same concentration

  • Peptide competition: Pre-incubation of antibody with excess immunizing peptide (PB2 a.a. 530-759)

  • Knockout/knockdown validation: CRISPR or siRNA targeting PB2 in recombinant systems

• Analytical techniques to confirm specificity:

  • Perform dose-response experiments with varying antibody concentrations

  • Compare results across multiple detection methods (e.g., Western blot, immunofluorescence)

  • Use recombinant PB2 fragments to map the detected epitope

• Cross-reactivity assessment:

  • Test the antibody against lysates from cells infected with other viral families

  • For bioengineered systems, test against cells expressing similar polymerase proteins

• Signal-to-noise optimization:

  • Implement additional blocking steps with 5% BSA or 5% milk

  • Increase washing stringency when background is high

  • Consider using detection systems with lower limits of detection for weak signals

This systematic approach to validating antibody specificity ensures reliable data interpretation, particularly in experiments involving multiple viral strains or host cell types. By implementing these controls, researchers can confidently attribute observed signals to specific PB2 detection rather than experimental artifacts .

What are the best approaches for quantitative analysis of PB2 expression using Anti-PB2 (clone# 3-1.6)?

For accurate quantitative analysis of PB2 expression using Anti-PB2 (clone# 3-1.6), researchers should implement these methodological approaches:

• Quantitative Western blotting:

  • Include a standard curve using recombinant PB2 (530-759) at known concentrations

  • Ensure linear dynamic range by testing multiple exposure times

  • Use fluorescent secondary antibodies rather than HRP for wider linear range

  • Normalize to appropriate loading controls (β-actin for whole cell, lamin for nuclear fractions)

  • Analyze band intensity using software like ImageJ with background subtraction

• Flow cytometry quantification:

  • For intracellular PB2 detection, fix cells with 4% paraformaldehyde and permeabilize with 0.1% Triton X-100

  • Use Anti-PB2 at 1:500 dilution followed by fluorophore-conjugated secondary antibody

  • Include calibration beads with known antibody binding capacity

  • Establish negative thresholds using uninfected cells and isotype controls

• ELISA-based quantification:

  • Develop a sandwich ELISA using Anti-PB2 (clone# 3-1.6) as capture or detection antibody

  • Generate standard curves with recombinant PB2 protein

  • Validate assay sensitivity and specificity using samples with known PB2 concentrations

  • Account for matrix effects by preparing standards in the same buffer as samples

• Advanced quantification considerations:

  • For absolute quantification, consider mass spectrometry approaches with labeled internal standards

  • For relative expression across conditions, ensure consistent sample processing

  • When comparing across viral strains, validate antibody binding efficiency to each strain's PB2

These quantitative approaches enable precise measurement of PB2 expression levels during viral infection, facilitating comparative studies of polymerase activity across different influenza strains or under various experimental conditions .